Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Serum sAPRIL: a potential tumor-associated biomarker to colorectal cancer.

Ding W, Wang J, Wang F, Wang G, Wu Q, Ju S, Cong H, Wang H.

Clin Biochem. 2013 Oct;46(15):1590-4. doi: 10.1016/j.clinbiochem.2013.06.008. Epub 2013 Jun 18.

PMID:
23792260
2.

Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.

Guadagni F, Kantor J, Aloe S, Carone MD, Spila A, D'Alessandro R, Abbolito MR, Cosimelli M, Graziano F, Carboni F, Carlini S, Perri P, Sciarretta F, Greiner JW, Kashmiri SV, Steinberg SM, Roselli M, Schlom J.

Cancer Res. 2001 Mar 15;61(6):2523-32.

3.

The diagnostic value of serum carcino-embryonic antigen, alpha fetoprotein and carbohydrate antigen 19-9 for colorectal cancer.

Wang YR, Yan JX, Wang LN.

J Cancer Res Ther. 2014 Dec;10 Suppl:307-9. doi: 10.4103/0973-1482.151538.

4.

Alu-based cell-free DNA: a potential complementary biomarker for diagnosis of colorectal cancer.

Qi J, Qian C, Shi W, Wu X, Jing R, Zhang L, Wang Z, Ju S.

Clin Biochem. 2013 Jan;46(1-2):64-9. doi: 10.1016/j.clinbiochem.2012.08.026. Epub 2012 Sep 10.

PMID:
22975639
5.

Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer.

He CZ, Zhang KH, Li Q, Liu XH, Hong Y, Lv NH.

BMC Gastroenterol. 2013 May 14;13:87. doi: 10.1186/1471-230X-13-87.

6.

Elevated serum synuclein-gamma in patients with gastrointestinal and esophageal carcinomas.

Liu C, Ma H, Qu L, Wu J, Meng L, Shou C.

Hepatogastroenterology. 2012 Oct;59(119):2222-7.

PMID:
22440249
7.

Identification of Cystatin SN as a novel tumor marker for colorectal cancer.

Yoneda K, Iida H, Endo H, Hosono K, Akiyama T, Takahashi H, Inamori M, Abe Y, Yoneda M, Fujita K, Kato S, Nozaki Y, Ichikawa Y, Uozaki H, Fukayama M, Shimamura T, Kodama T, Aburatani H, Miyazawa C, Ishii K, Hosomi N, Sagara M, Takahashi M, Ike H, Saito H, Kusakabe A, Nakajima A.

Int J Oncol. 2009 Jul;35(1):33-40.

PMID:
19513549
8.

Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases.

Yang XQ, Chen C, Peng CW, Liu SP, Li Y.

Med Oncol. 2012 Jun;29(2):1030-6. doi: 10.1007/s12032-011-9967-z. Epub 2011 May 7.

PMID:
21553105
9.

Comparative analysis of tumor markers and evaluation of their predictive value in patients with colorectal cancer.

Liu ZP, Li LM, Liu XL, Zhang DX.

Onkologie. 2012;35(3):108-13. doi: 10.1159/000336816. Epub 2012 Feb 20.

PMID:
22414974
10.

Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19-9 for colorectal carcinoma.

Zhang SY, Lin M, Zhang HB.

Int J Clin Exp Pathol. 2015 Aug 1;8(8):9404-9. eCollection 2015.

11.

Stem cell factor (SCF) and interleukin 3 (IL-3) in the sera of patients with colorectal cancer.

Mroczko B, Szmitkowski M, Wereszczyńska-Siemiatkowska U, Okulczyk B.

Dig Dis Sci. 2005 Jun;50(6):1019-24.

PMID:
15986847
12.

Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer.

Song YF, Xu ZB, Zhu XJ, Tao X, Liu JL, Gao FL, Wu CL, Song B, Lin Q.

Clin Transl Oncol. 2017 Apr;19(4):519-524. doi: 10.1007/s12094-016-1560-7. Epub 2016 Oct 14.

PMID:
27743169
13.

Preoperative serum carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer.

Yang XQ, Li Y, Chen C, Peng CW, Liu SP, Liu Y.

Med Oncol. 2011 Sep;28(3):789-95. doi: 10.1007/s12032-010-9518-z. Epub 2010 Apr 7.

PMID:
20373053
14.
15.

Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.

Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R.

Anticancer Res. 2000 Nov-Dec;20(6D):5195-8.

PMID:
11326694
16.
17.

Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis.

Körner H, Söreide K, Stokkeland PJ, Söreide JA.

Ann Surg Oncol. 2007 Feb;14(2):417-23.

PMID:
17103264
18.

[Usefulness of preoperative assay CEA and CA 19-9 in colorectal cancer patients].

Grotowski M, Maruszyński M, Piechota W.

Pol Merkur Lekarski. 2001 Dec;11(66):476-9. Polish.

PMID:
11899841
19.

Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.

Herszényi L, Farinati F, Cardin R, István G, Molnár LD, Hritz I, De Paoli M, Plebani M, Tulassay Z.

BMC Cancer. 2008 Jul 10;8:194. doi: 10.1186/1471-2407-8-194.

20.

Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?

Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chang SC.

J Surg Res. 2005 Apr;124(2):169-74.

PMID:
15820244

Supplemental Content

Support Center